DNA vaccine trains immune system to fight brain cancer
NCT ID NCT05698199
First seen Jun 29, 2026 · Last updated Jul 01, 2026 · Updated 2 times
Summary
This early-stage trial tests a DNA vaccine called ITI-1001 in people with newly diagnosed glioblastoma, an aggressive brain cancer. The vaccine is designed to teach the immune system to recognize and attack cancer cells that carry common cytomegalovirus (CMV) proteins. About 10 participants who have had surgery and will receive standard chemoradiation will get the vaccine to see if it is safe and triggers an immune response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ITI-1001 (DNA vaccine targeting CMV antigens)
What this could lead to
If successful, this could point toward a new immunotherapy approach to help control glioblastoma by training the immune system to attack tumor cells.
What could go wrong
This is a very early, small phase I trial focused on safety, so it may not show clear benefit. The vaccine targets CMV proteins, which may not be present in all tumors, and side effects are unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States